Indication
T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature T-cell lymphoblasts in the bone marrow and peripheral blood. Read more about T-cell acute lymphoblastic leukemia
13 drugs 13 manufacturers
Drugs that treat it
Common T-cell acute lymphoblastic leukemia therapies.
ARRANON (nelarabine)
NELARABINE
NELARABINE
NELARABINE
NELARABINE
NELARABINE
NELARABINE
NELARABINE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonT-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature T-cell lymphoblasts in the bone marrow and peripheral blood.
It affects the lymphoid and hematopoietic systems across both pediatric and adult populations, accounting for approximately 10% to 15% of childhood and up to 25% of adult acute lymphoblastic leukemia cases.
Pathophysiologically, the disease arises from multistep oncogenic mutations—such as activating alterations in *NOTCH1*—that cause differentiation arrest during thymocyte development.
Clinically, it frequently presents with marked leukocytosis, bone marrow failure causing cytopenias, an anterior mediastinal mass from thymic expansion, and a predilection for central nervous system infiltration.
- cancer.gov
T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature T-cell lymphoblasts in the bone marrow and peripheral blood
- nih.gov
T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature T-cell lymphoblasts in the bone marrow and peripheral blood It affects the lymphoid and hematopoietic systems across both pediatric and adult populations, accounting for approximately 10% to 15% of childhood and up to 25% of adult acute lymphoblastic leukemia cases Pathophysiologically, the disease arises from multistep oncogenic mutations—such ...
- leukemiarf.org
It affects the lymphoid and hematopoietic systems across both pediatric and adult populations, accounting for approximately 10% to 15% of childhood and up to 25% of adult acute lymphoblastic leukemia cases Clinically, it frequently presents with marked leukocytosis, bone marrow failure causing cytopenias, an anterior mediastinal mass from thymic expansion, and a predilection for central nervous system infiltration
- nih.gov
Pathophysiologically, the disease arises from multistep oncogenic mutations—such as activating alterations in *NOTCH1*—that cause differentiation arrest during thymocyte development Clinically, it frequently presents with marked leukocytosis, bone marrow failure causing cytopenias, an anterior mediastinal mass from thymic expansion, and a predilection for central nervous system infiltration
- nih.gov
Clinically, it frequently presents with marked leukocytosis, bone marrow failure causing cytopenias, an anterior mediastinal mass from thymic expansion, and a predilection for central nervous system infiltration
Personalize your experience
Follow T-cell acute lymphoblastic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.